-
Posted by
Two Blokes Jul 14 -
Filed in
Stock
-
1 view
NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for its lead candidate NV-387 to treat MPox virus Clade 1a and 1b infections. The trial aims to assess safety, tolerability, and antiviral effectiveness in approximately 80 patients, with the initial Phase IIa portion to be conducted at a single site in the Democratic Republic of Congo (DRC).
